[MP-202623] Daraxonrasib (Metastatic pancreatic adenocarcinoma)
Last updated 28.07.2026
Project no.:
MP-202623
Report type:
Joint Clinical Assessment, JCA
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Metastatic pancreatic adenocarcinoma
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Danish Medicines Council, Denmark.
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| Start | 3rd quarter, 2026 |